Preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are associated with major adverse cardiovascular and cerebrovascular events in coronary heart disease patients undergoing non-cardiac surgery.
Blood cell count
Coronary heart disease
Neutrophil to lymphocyte ratio
Perioperative care
Platelet to lymphocyte ratio
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
18 05 2020
18 05 2020
Historique:
received:
02
08
2019
accepted:
30
04
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
25
11
2020
Statut:
epublish
Résumé
Preoperative risk prediction in patients at elevated cardiovascular risk shows limited accuracy. Platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR) indicate systemic inflammation. Both have been investigated for outcome prediction in the field of oncology and cardiovascular medicine, as well as risk prediction of adverse cardiovascular events in non-surgical patients at increased cardiovascular risk. For this post-hoc analysis, we included all 38 coronary heart disease patients from the Leukocytes and Cardiovascular Perioperative Events cohort-1 study scheduled for elective non-cardiac surgery. We evaluated preoperative differential blood counts for association with major adverse cardiovascular and cerebrovascular events (MACCE) defined as the composite endpoint of death, myocardial ischemia, myocardial infarction, myocardial injury after non-cardiac surgery, or embolic or thrombotic stroke within 30 days after surgery. We used Youden's index to calculate cut-off values for PLR and NLR. Additive risk-predictive values were assessed using receiver operating characteristic curve and net reclassification (NRI) improvement analyses. Patients with the composite endpoint MACCE had higher PLR and NLR (309 [206; 380] vs. 160 [132; 203], p = 0.001; 4.9 [3.5; 8.1] vs. 2.6 [2.2; 3.4]), p = 0.001). Calculated cut-offs for PLR > 204.4 and NLR > 3.1 were associated with increased risk of 30-day MACCE (OR 7, 95% CI [1.2; 44.7], p = 0.034; OR 36, 95% CI [1.8; 686.6], p = 0.001). Furthermore, NLR improved risk prediction in coronary heart disease patients undergoing non-cardiac surgery when combined with hs-cTnT or NT-proBNP (NRI Both PLR and NLR were associated with perioperative cardiovascular adverse events in coronary heart disease patients. NLR proved to be of additional value for preoperative risk stratification. Both PLR and NLR could be used as inexpensive and broadly available tools for perioperative risk assessment. NCT02874508, August 22, 2016.
Sections du résumé
BACKGROUND
Preoperative risk prediction in patients at elevated cardiovascular risk shows limited accuracy. Platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR) indicate systemic inflammation. Both have been investigated for outcome prediction in the field of oncology and cardiovascular medicine, as well as risk prediction of adverse cardiovascular events in non-surgical patients at increased cardiovascular risk.
METHODS
For this post-hoc analysis, we included all 38 coronary heart disease patients from the Leukocytes and Cardiovascular Perioperative Events cohort-1 study scheduled for elective non-cardiac surgery. We evaluated preoperative differential blood counts for association with major adverse cardiovascular and cerebrovascular events (MACCE) defined as the composite endpoint of death, myocardial ischemia, myocardial infarction, myocardial injury after non-cardiac surgery, or embolic or thrombotic stroke within 30 days after surgery. We used Youden's index to calculate cut-off values for PLR and NLR. Additive risk-predictive values were assessed using receiver operating characteristic curve and net reclassification (NRI) improvement analyses.
RESULTS
Patients with the composite endpoint MACCE had higher PLR and NLR (309 [206; 380] vs. 160 [132; 203], p = 0.001; 4.9 [3.5; 8.1] vs. 2.6 [2.2; 3.4]), p = 0.001). Calculated cut-offs for PLR > 204.4 and NLR > 3.1 were associated with increased risk of 30-day MACCE (OR 7, 95% CI [1.2; 44.7], p = 0.034; OR 36, 95% CI [1.8; 686.6], p = 0.001). Furthermore, NLR improved risk prediction in coronary heart disease patients undergoing non-cardiac surgery when combined with hs-cTnT or NT-proBNP (NRI
CONCLUSIONS
Both PLR and NLR were associated with perioperative cardiovascular adverse events in coronary heart disease patients. NLR proved to be of additional value for preoperative risk stratification. Both PLR and NLR could be used as inexpensive and broadly available tools for perioperative risk assessment.
TRIAL REGISTRATION
NCT02874508, August 22, 2016.
Identifiants
pubmed: 32423376
doi: 10.1186/s12872-020-01500-6
pii: 10.1186/s12872-020-01500-6
pmc: PMC7236311
doi:
Banques de données
ClinicalTrials.gov
['NCT02874508']
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
230Subventions
Organisme : Klinik für Anästhesiologie UniversitätsKlinikum Heidelberg
ID : n.a.
Pays : International
Références
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Can J Cardiol. 2017 Jan;33(1):17-32
pubmed: 27865641
Ann Intern Med. 2010 Jan 5;152(1):26-35
pubmed: 20048269
Eur J Anaesthesiol. 2014 Oct;31(10):517-73
pubmed: 25127426
Clin Exp Nephrol. 2020 Feb;24(2):126-135
pubmed: 31650334
Clin Appl Thromb Hemost. 2016 Jul;22(5):405-11
pubmed: 25667237
Int J Cardiol. 2018 Sep 1;266:31-37
pubmed: 29887466
Anesth Analg. 2019 Jun;128(6):1344-1353
pubmed: 31094810
J Mol Cell Cardiol. 2020 Jan;138:158-164
pubmed: 31812706
J Leukoc Biol. 2020 May;107(5):717-730
pubmed: 31523852
Clin Chim Acta. 2018 Aug;483:48-56
pubmed: 29678631
Heart. 2012 May;98(10):792-8
pubmed: 22543837
Science. 2013 Jan 11;339(6116):161-6
pubmed: 23307733
Clin Chem. 2010 Apr;56(4):642-50
pubmed: 20167697
Anesthesiology. 2014 Mar;120(3):564-78
pubmed: 24534856
Vasc Endovascular Surg. 2011 Apr;45(3):227-31
pubmed: 21289130
Acta Diabetol. 2019 Jul;56(7):741-748
pubmed: 30993529
Heart Lung. 2018 May - Jun;47(3):243-247
pubmed: 29500104
J Neurol Sci. 2019 Nov 15;406:116445
pubmed: 31521961
J Thromb Thrombolysis. 2012 Oct;34(3):326-34
pubmed: 22466812
Am J Cardiol. 2010 Aug 15;106(4):470-6
pubmed: 20691303
Eur J Epidemiol. 2019 May;34(5):463-470
pubmed: 30569368
Braz J Cardiovasc Surg. 2018 May-Jun;33(3):233-241
pubmed: 30043915
Int J Surg. 2012;10(3):157-62
pubmed: 22361307
Angiology. 2012 Apr;63(3):213-7
pubmed: 21733954
J Cardiovasc Med (Hagerstown). 2020 Jan;21(1):80-82
pubmed: 31567635
BMC Cardiovasc Disord. 2018 May 2;18(1):75
pubmed: 29716535
Ann Thorac Surg. 2018 Feb;105(2):581-586
pubmed: 29132702
Br J Anaesth. 2019 Feb;122(2):180-187
pubmed: 30686303
Front Neurol. 2019 Oct 04;10:1032
pubmed: 31636598
Platelets. 2015;26(7):680-1
pubmed: 25549287
Neurocrit Care. 2019 Oct 15;:
pubmed: 31617117
J Am Coll Cardiol. 2005 May 17;45(10):1638-43
pubmed: 15893180
ANZ J Surg. 2015 Jun;85(6):414-9
pubmed: 25781147
Vasc Endovascular Surg. 2019 Jan;53(1):5-11
pubmed: 30021492
Front Cardiovasc Med. 2020 Feb 18;7:13
pubmed: 32133374